Get the Stockscreener App
25.99
2.44%
0.62
After Hours:
25.99
Fulgent Genetics Inc stock is traded at $25.99, with a volume of 204.53K.
It is up +2.44% in the last 24 hours and down -6.48% over the past month.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
See More
Previous Close:
$25.37
Open:
$25.25
24h Volume:
204.53K
Relative Volume:
0.79
Market Cap:
$803.41M
Revenue:
$290.71M
Net Income/Loss:
$-163.43M
P/E Ratio:
-4.7427
EPS:
-5.48
Net Cash Flow:
$11.70M
1W Performance:
-1.89%
1M Performance:
-6.48%
6M Performance:
+29.56%
1Y Performance:
+38.39%
1-Day Range:
$25.07
$26.00
1-Week Range:
$25.07
$26.55
52-Week Range:
$14.76
$31.04
Fulgent Genetics Inc Stock (FLGT) Company Profile
Name
Fulgent Genetics Inc
Sector
Industry
Phone
626-350-0537
Address
4399 SANTA ANITA AVE, EL MONTE
Compare FLGT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FLGT
Fulgent Genetics Inc
|
25.99 | 784.25M | 290.71M | -163.43M | 11.70M | -5.48 |
|
TMO
Thermo Fisher Scientific Inc
|
620.72 | 229.63B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
236.59 | 166.25B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
706.83 | 54.48B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
147.60 | 40.52B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
240.53 | 39.95B | 15.90B | 1.28B | 2.21B | 7.2842 |
Fulgent Genetics Inc Stock (FLGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Upgrade | UBS | Neutral → Buy |
| Dec-07-23 | Initiated | UBS | Neutral |
| Dec-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-18-22 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Feb-04-22 | Resumed | Piper Sandler | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Underperform |
| Jan-08-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Nov-24-20 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-20-20 | Initiated | Oppenheimer | Outperform |
| May-29-20 | Initiated | BTIG Research | Buy |
| Nov-05-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Mar-01-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Nov-07-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Fulgent Genetics Inc Stock (FLGT) Latest News
Fulgent Genetics (NASDAQ:FLGT) vs. Mitesco (OTCMKTS:MITI) Critical Analysis - Defense World
Liquidity Mapping Around (FLGT) Price Events - Stock Traders Daily
FLGT to acquire Bako & StrataDx assets to expand pathology platform - MSN
Squarepoint Ops LLC Cuts Position in Fulgent Genetics, Inc. $FLGT - MarketBeat
FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform - Finviz
Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx - BioSpace
Fulgent Genetics to acquire StrataDx and selected assets of Bako Diagnostics - Medical Buyer
Fulgent Genetics to acquire select assets of Bako Diagnostics and StrataDx for $55.5m - pehub.com
Fulgent Genetics to buy Bako Diagnostics assets and StrataDx - Yahoo Finance
Latham & Watkins Advises on Fulgent Genetics’ Acquisition of Bako Diagnostics and StrataDX - Legal Desire Media and Insights
Fulgent Genetics to Acquire Bako Diagnostics and StrataDx - citybiz
Fulgent Genetics to acquire Bako Diagnostics and StrataDx for $55.5 million - Investing.com Nigeria
Fulgent Genetics to acquire Bako Diagnostics and StrataDx for $55.5 million By Investing.com - Investing.com South Africa
Fulgent Genetics (FLGT) to Acquire Assets from Bako Diagnostics and StrataDx - GuruFocus
Fulgent Genetics to Acquire Bako Diagnostics and StrataDx for $55.5 Million - marketscreener.com
How Fulgent Genetics Inc. stock performs during Fed tightening cyclesJuly 2025 Macro Moves & Precise Swing Trade Alerts - Улправда
Why Fulgent Genetics Inc. (7F0) stock attracts wealthy investorsForecast Cut & Advanced Technical Signal Analysis - Улправда
Understanding the Setup: (FLGT) and Scalable Risk - Stock Traders Daily
How Fulgent Genetics Inc. stock performs in rate cut cyclesJuly 2025 Levels & Free Safe Entry Trade Signal Reports - ulpravda.ru
Will Fulgent Genetics Inc. stock outperform tech sector in 2025Analyst Downgrade & Real-Time Price Movement Reports - Улправда
Will Fulgent Genetics Inc. stock outperform value stocksMarket Trend Review & Verified Short-Term Plans - Улправда
Will Fulgent Genetics Inc. stock continue dividend increasesWeekly Earnings Recap & Intraday High Probability Setup Alerts - Улправда
Is Fulgent Genetics Inc. stock a buy before product launchesPortfolio Update Report & Entry Point Confirmation Signals - DonanımHaber
Published on: 2025-12-19 03:22:26 - Улправда
Why Fulgent Genetics Inc. stock remains on buy listsJuly 2025 Chart Watch & Accurate Intraday Trade Tips - Улправда
How Fulgent Genetics Inc. stock performs in stagflationRate Cut & Entry and Exit Point Strategies - Улправда
Fulgent Genetics (NASDAQ:FLGT) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
Fulgent Genetics (NASDAQ:FLGT) Rating Lowered to “Hold” at Wall Street Zen - Defense World
The Technical Signals Behind (FLGT) That Institutions Follow - Stock Traders Daily
Fulgent Genetics Shares Surge on Unexpected Profit and Raised Outlook - AD HOC NEWS
Diametric Capital LP Makes New $3.36 Million Investment in Fulgent Genetics, Inc. $FLGT - MarketBeat
Fulgent Genetics (NASDAQ:FLGT) Insider Sells $30,454.75 in Stock - MarketBeat
How Fulgent Genetics Inc. (7F0) stock performs during market turbulenceTrade Volume Report & Low Risk Growth Stock Ideas - Newser
Can Fulgent Genetics Inc. (7F0) stock resist broad market declinesWeekly Trend Report & Safe Entry Point Identification - Newser
Will Fulgent Genetics Inc. (7F0) stock outperform value peersWall Street Watch & Long-Term Investment Growth Plans - Newser
Fulgent Genetics Executives Sell Shares for Tax Obligations - TradingView — Track All Markets
What macro factors could drive Fulgent Genetics Inc. (7F0) stock higherAnalyst Downgrade & Daily Volume Surge Signals - Newser
Creative Planning Has $796,000 Stake in Fulgent Genetics, Inc. $FLGT - Defense World
Will Fulgent Genetics Inc. (7F0) stock boost dividends furtherEarnings Overview Report & Consistent Return Strategy Ideas - Newser
Fulgent Genetics (NASDAQ:FLGT) Insider Hanlin Gao Sells 943 Shares - MarketBeat
Fulgent Genetics: From Genetic Code To Cancer CureWhy I Assign A Hold Rating (NASDAQ:FLGT) - Seeking Alpha
Can Fulgent Genetics Inc. (7F0) stock surprise with quarterly resultsMarket Trend Summary & Verified Entry Point Detection - Newser
Fulgent Genetics CSO Gao Hanlin sells $27884 in stock By Investing.com - Investing.com South Africa
Fulgent Genetics Inc Stock (FLGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fulgent Genetics Inc Stock (FLGT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gao Hanlin | Chief Scientific Officer |
Dec 02 '25 |
Sale |
28.33 |
1,075 |
30,457 |
952,890 |
| Xie Jian | President and COO |
Nov 28 '25 |
Sale |
29.57 |
1,198 |
35,424 |
337,889 |
| Gao Hanlin | Chief Scientific Officer |
Nov 28 '25 |
Sale |
29.57 |
943 |
27,884 |
953,965 |
2.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):